Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. (Q39734394)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Wendy Barclay

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

L C S Hartgroves

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

W Koudstaal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

C McLeod

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

C I Thompson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J Ellis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

C Bull

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M J E Havenga

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J Goudsmit

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

25 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

2973-2979

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20188682%20AND%20SRC:MED&resulttype=core&format=json

Hemagglutinin residues of recent human A(H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Evidence for host-cell selection of influenza virus antigenic variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Stabilizing the glycosylation pattern of influenza B hemagglutinin following adaptation to growth in eggs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

The growth of attenuated influenza vaccine donor strains in continuous cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Generation of influenza A viruses entirely from cloned cDNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

NS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta interferon response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Receptor binding specificity of recent human H3N2 influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Functional balance between haemagglutinin and neuraminidase in influenza virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Enhanced growth of seed viruses for H5N1 influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012

Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.012